Bernstein Sees Eli Lilly Stock (LLY) Hitting $1,300 Per Share

Wall Street brokerage Bernstein sees Eli Lilly’s (LLY) stock hitting $1,300 per share.

Analysts at Bernstein have reiterated a Buy-equivalent outperform rating on LLY stock with a price target of $1,300, representing 25% upside from current levels. The new price target from Bernstein is one of the highest on Wall Street but below the top target of $1,500 a share.

In a note to clients, Bernstein stresses that Eli Lilly will focus this year on its new weight-loss pill that is expected to launch globally by the summer, along with the international expansion of its diabetes and arthritis medications.

Eli Lilly’s Growth Trajectory

Bernstein adds that Eli Lilly’s growth trajectory remains impressive, with 45% revenue growth over the past 12 months. The Wall Street firm said that it remains confident in Eli Lilly’s financial health and believes that the company is well-positioned for another year of outperformance in 2026.

The appraisal ends with Bernstein naming Eli Lilly its “top stock pick” in the pharmaceutical sector with a $1,300 price target for 2026. Analysts at Bernstein stress that they aren’t concerned about a delayed decision from the U.S. Food and Drug Administration (FDA) on Eli Lilly’s weight-loss pill, which is now expected by April 10. The new timing keeps the weight-loss pill’s launch on track, said Bernstein.

Is LLY Stock a Buy?

The stock of Eli Lilly has a consensus Strong Buy rating among 20 Wall Street analysts. That rating is based on 18 Buy and two Hold recommendations issued in the last three months. The average LLY price target of $1,191.89 implies 10.51% upside from current levels.

Read more analyst ratings on LLY stock